195 related articles for article (PubMed ID: 17121907)
1. A novel HSV-1 virus, JS1/34.5-/47-, purges contaminating breast cancer cells from bone marrow.
Hu JC; Booth MJ; Tripuraneni G; Davies D; Zaidi SA; Tamburo de Bella M; Slade MJ; Marley SB; Gordon MY; Coffin RS; Coombes RC; Kamalati T
Clin Cancer Res; 2006 Nov; 12(22):6853-62. PubMed ID: 17121907
[TBL] [Abstract][Full Text] [Related]
2. Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation.
Wu A; Mazumder A; Martuza RL; Liu X; Thein M; Meehan KR; Rabkin SD
Cancer Res; 2001 Apr; 61(7):3009-15. PubMed ID: 11306480
[TBL] [Abstract][Full Text] [Related]
3. Biological purging of breast cancer cell lines using a replication-competent oncolytic virus in human stem cell autografts.
Thirukkumaran CM; Luider JM; Stewart DA; Alain T; Russell JA; Auer IA; Forsyth P; Morris DG
Bone Marrow Transplant; 2005 Jun; 35(11):1055-64. PubMed ID: 15821774
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10.
Teshigahara O; Goshima F; Takao K; Kohno S; Kimata H; Nakao A; Nishiyama Y
J Surg Oncol; 2004 Jan; 85(1):42-7. PubMed ID: 14696086
[TBL] [Abstract][Full Text] [Related]
5. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus.
Fu X; Tao L; Cai R; Prigge J; Zhang X
Mol Ther; 2006 May; 13(5):882-90. PubMed ID: 16569513
[TBL] [Abstract][Full Text] [Related]
6. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
[TBL] [Abstract][Full Text] [Related]
7. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.
Fu X; Zhang X
Cancer Res; 2002 Apr; 62(8):2306-12. PubMed ID: 11956088
[TBL] [Abstract][Full Text] [Related]
8. Bovine herpesvirus type 1 as a novel oncolytic virus.
Rodrigues R; Cuddington B; Mossman K
Cancer Gene Ther; 2010 May; 17(5):344-55. PubMed ID: 19893594
[TBL] [Abstract][Full Text] [Related]
9. Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation.
Shpall EJ; Bast RC; Joines WT; Jones RB; Anderson I; Johnston C; Eggleston S; Tepperberg M; Edwards S; Peters WP
Bone Marrow Transplant; 1991 Feb; 7(2):145-51. PubMed ID: 2049558
[TBL] [Abstract][Full Text] [Related]
10. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.
Li H; Dutuor A; Fu X; Zhang X
J Gene Med; 2007 Mar; 9(3):161-9. PubMed ID: 17266169
[TBL] [Abstract][Full Text] [Related]
11. Effect of a caspase inhibitor, zVADfmk, on the inhibition of breast cancer cells by herpes simplex virus type 1.
Wood LW; Shillitoe EJ
Cancer Gene Ther; 2011 Oct; 18(10):685-94. PubMed ID: 21701533
[TBL] [Abstract][Full Text] [Related]
12. Establishment of a novel foreign gene delivery system combining an HSV amplicon with an attenuated replication-competent virus, HSV-1 HF10.
Zhang L; Daikoku T; Ohtake K; Ohtsuka J; Nawa A; Kudoh A; Iwahori S; Isomura H; Nishiyama Y; Tsurumi T
J Virol Methods; 2006 Nov; 137(2):177-83. PubMed ID: 16854473
[TBL] [Abstract][Full Text] [Related]
13. Purging breast cancer cells in preparation for autologous bone marrow transplantation.
Morecki S; Pavlotzky F; Margel S; Slavin S
Bone Marrow Transplant; 1987 Apr; 1(4):357-63. PubMed ID: 3332143
[TBL] [Abstract][Full Text] [Related]
14. Detection of tumor cells in the bone marrow, peripheral blood, and apheresis products of breast cancer patients using flow cytometry.
Simpson SJ; Vachula M; Kennedy MJ; Kaizer H; Coon JS; Ghalie R; Williams S; Van Epps D
Exp Hematol; 1995 Sep; 23(10):1062-8. PubMed ID: 7544737
[TBL] [Abstract][Full Text] [Related]
15. An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16.
Griffith C; Noonan S; Lou E; Shillitoe EJ
Cancer Gene Ther; 2007 Dec; 14(12):985-93. PubMed ID: 17853922
[TBL] [Abstract][Full Text] [Related]
16. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
Fu X; Tao L; Zhang X
Cancer Gene Ther; 2007 May; 14(5):480-7. PubMed ID: 17290283
[TBL] [Abstract][Full Text] [Related]
17. Herpes simplex virus 1 (HSV-1) for cancer treatment.
Shen Y; Nemunaitis J
Cancer Gene Ther; 2006 Nov; 13(11):975-92. PubMed ID: 16604059
[TBL] [Abstract][Full Text] [Related]
18. [Progess on research of herpes simplex virus type 1 mutants for cancer therapy].
Long Y; Mi Y; Li Y
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Dec; 25(6):1446-9. PubMed ID: 19166228
[TBL] [Abstract][Full Text] [Related]
19. Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants.
Mahller YY; Rangwala F; Ratner N; Cripe TP
Pediatr Blood Cancer; 2006 Jun; 46(7):745-54. PubMed ID: 16124003
[TBL] [Abstract][Full Text] [Related]
20. Elimination of malignant clonogenic breast cancer cells from human bone marrow.
Anderson IC; Shpall EJ; Leslie DS; Nustad K; Ugelstad J; Peters WP; Bast RC
Cancer Res; 1989 Aug; 49(16):4659-64. PubMed ID: 2663144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
